H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results
On May 27, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio, Inc. (NASDAQ:TRML) while keeping the price target at $50.
Tourmaline Bio Inc. (TRML)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 2,555,555 | $122,232,196 | 1.58% | |
| 2. | QVT Financial Daniel Gold | 2,154,653 | $103,057,053 | 7.27% | |
| 3. | Magnetar Capital Alec Litowitz And Ross Laser | 966,129 | $46,209,950 | 0.28% | |
| 4. | TIG Advisors Carl Tiedemann And Michael Tiedemann | 619,763 | $29,643,264 | 1.76% | |
| 5. | Vivo Capital Albert Cha And Frank Kung | 591,882 | $28,309,716 | 2.28% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.85 | 1,779 | $26,418.15 | 7,000 | 2024-08-21 | Filing | |
| $13.79 | 5,221 | $71,997.59 | 5,221 | 2024-08-16 | Filing | |
| $32.50 | 100,000 | $3,250,000.00 | 448,431 | 2024-01-29 | Filing | |
| $16.99 | 4,000 | $67,960.00 | 729,735 | 2023-11-17 | Filing | |
| $17.31 | 1,000 | $17,310.00 | 83,782 | 2023-11-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.49 | 12,942 | $32,243.70 | 3,771,392 | 2023-06-14 | Filing | |
| $2.56 | 14,208 | $36,338.38 | 3,784,334 | 2023-06-13 | Filing | |
| $2.59 | 16,870 | $43,725.35 | 3,798,542 | 2023-06-12 | Filing | |
| $2.46 | 25,419 | $62,637.50 | 3,815,412 | 2023-06-09 | Filing | |
| $2.48 | 40,642 | $100,771.84 | 3,840,831 | 2023-06-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,517,777 | $72,595,275 | 0% | |
| 2. | 1,272,214 | $60,849,996 | 13.91% | |
| 3. | 1,165,607 | $55,750,983 | 0% | |
| 4. | 1,027,690 | $49,154,413 | 0.04% | |
| 5. | 741,691 | $35,475,081 | 63.76% |
News See All
BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)
The firm believes that the market’s negative reaction to Phase II data for the company’s drug, Paci, was excessive.